IL2 and type 1 diabetes mellitus: Our study adds to the good track record of using low-dose recombinant IL-2 and confirms its very strong safety profile, which is critical for the potential long-term use of LD-IL-2 immunotherapy for diseases such as T1D in which the target patient population will consist mainly of children, including the possible future use of iLD-IL-2 treatment in the prevention of T1D diagnosis.